Reported Earnings • May 16
First quarter 2026 earnings released: NT$0.37 loss per share (vs NT$0.39 loss in 1Q 2025) First quarter 2026 results: NT$0.37 loss per share (improved from NT$0.39 loss in 1Q 2025). Revenue: NT$6.12m (up 14% from 1Q 2025). Net loss: NT$13.0m (loss narrowed 5.0% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 14
Full year 2025 earnings released: NT$1.30 loss per share (vs NT$1.54 loss in FY 2024) Full year 2025 results: NT$1.30 loss per share (improved from NT$1.54 loss in FY 2024). Revenue: NT$27.0m (up 16% from FY 2024). Net loss: NT$45.8m (loss narrowed 16% from FY 2024). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Ankündigung • Mar 11
SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 17, 2026 SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 17, 2026. Location: no,95, hsin liao rd., chung shan ts`u, dongshan township, yilan county Taiwan Reported Earnings • Nov 19
Third quarter 2025 earnings released: NT$0.23 loss per share (vs NT$0.41 loss in 3Q 2024) Third quarter 2025 results: NT$0.23 loss per share (improved from NT$0.41 loss in 3Q 2024). Revenue: NT$6.47m (up 22% from 3Q 2024). Net loss: NT$8.04m (loss narrowed 44% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 17
Second quarter 2025 earnings released: NT$0.33 loss per share (vs NT$0.38 loss in 2Q 2024) Second quarter 2025 results: NT$0.33 loss per share (improved from NT$0.38 loss in 2Q 2024). Revenue: NT$7.82m (up 10% from 2Q 2024). Net loss: NT$11.7m (loss narrowed 13% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Reported Earnings • May 18
First quarter 2025 earnings released: NT$0.39 loss per share (vs NT$0.38 loss in 1Q 2024) First quarter 2025 results: NT$0.39 loss per share (further deteriorated from NT$0.38 loss in 1Q 2024). Revenue: NT$5.39m (up 23% from 1Q 2024). Net loss: NT$13.7m (loss widened 2.1% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Ankündigung • Feb 27
SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 20, 2025 SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 20, 2025. Location: no,95, hsin liao rd., chung shan ts`u, dongshan township, yilan county Taiwan Reported Earnings • Aug 18
Second quarter 2024 earnings released: NT$0.38 loss per share (vs NT$0.86 loss in 2Q 2023) Second quarter 2024 results: NT$0.38 loss per share (improved from NT$0.86 loss in 2Q 2023). Net loss: NT$13.5m (loss narrowed 49% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. New Risk • Apr 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$20m revenue, or US$631k). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (NT$1.95b market cap, or US$61.0m). Ankündigung • Mar 27
SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 18, 2024 SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 18, 2024. Reported Earnings • Mar 21
Full year 2023 earnings released: NT$1.19 loss per share (vs NT$6.14 loss in FY 2022) Full year 2023 results: NT$1.19 loss per share (improved from NT$6.14 loss in FY 2022). Net loss: NT$38.2m (loss narrowed 80% from FY 2022). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. New Risk • Nov 15
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$18m revenue, or US$555k). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (NT$1.24b market cap, or US$38.8m). New Risk • Jul 01
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 274% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (274% increase in shares outstanding). Revenue is less than US$1m (NT$16m revenue, or US$520k). Reported Earnings • Mar 09
Full year 2022 earnings released: NT$1.64 loss per share (vs NT$4.04 loss in FY 2021) Full year 2022 results: NT$1.64 loss per share (improved from NT$4.04 loss in FY 2021). Net loss: NT$188.7m (loss narrowed 59% from FY 2021). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Fu-Hsing Chang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Aug 16
Second quarter 2022 earnings released: NT$0.30 loss per share (vs NT$0.77 loss in 2Q 2021) Second quarter 2022 results: NT$0.30 loss per share (up from NT$0.77 loss in 2Q 2021). Net loss: NT$34.0m (loss narrowed 62% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Fu-Hsing Chang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 13
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: NT$4.04 loss per share (down from NT$3.83 loss in FY 2020). Net loss: NT$458.6m (loss widened 15% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 7% per year. Reported Earnings • Nov 15
Third quarter 2021 earnings released: NT$1.90 loss per share (vs NT$0.96 loss in 3Q 2020) Third quarter 2021 results: Net loss: NT$218.7m (loss widened 114% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 13
Second quarter 2021 earnings released: NT$0.77 loss per share (vs NT$1.08 loss in 2Q 2020) Second quarter 2021 results: Net loss: NT$88.2m (loss narrowed 20% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 16
First quarter 2021 earnings released: NT$0.65 loss per share (vs NT$0.87 loss in 1Q 2020) First quarter 2021 results: Net loss: NT$71.6m (loss narrowed 15% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Reported Earnings • Mar 24
Full year 2020 earnings released: NT$3.83 loss per share (vs NT$4.54 loss in FY 2019) Full year 2020 results: Net loss: NT$398.9m (loss narrowed 2.4% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 23
New 90-day high: NT$54.30 The company is up 11% from its price of NT$48.70 on 25 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 7.0% over the same period. Is New 90 Day High Low • Jan 29
New 90-day low: NT$39.95 The company is down 17% from its price of NT$48.30 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 16% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: NT$44.10 The company is down 21% from its price of NT$55.90 on 14 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 15% over the same period. Reported Earnings • Nov 14
Third quarter 2020 earnings released: NT$0.96 loss per share Third quarter 2020 results: Net loss: NT$102.0m (loss narrowed 7.9% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Oct 31
New 90-day low: NT$48.30 The company is down 33% from its price of NT$72.20 on 31 July 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Is New 90 Day High Low • Oct 08
New 90-day low: NT$58.20 The company is down 58% from its price of NT$137 on 10 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 25% over the same period.